Loading...
•
Jun 30, 2024
Nuvectis Pharma Q2 2024 Earnings Report
Nuvectis Pharma reported financial results for the second quarter of 2024 and provided an update on recent business progress.
Key Takeaways
Nuvectis Pharma reported a net loss of $4.4 million for the second quarter of 2024, with cash and cash equivalents totaling $18.1 million as of June 30, 2024. The company is advancing clinical trials for NXP800 and NXP900 and managing financial resources effectively.
Advanced clinical trials for NXP800 and NXP900.
NXP800 Phase 1b clinical trial in platinum resistant, ARID1a-mutated ovarian cancer is continuing to enroll patients.
NXP900 dose escalation clinical trial is ongoing with no reports of dose limiting toxicities in the first three cohorts.
Cash and cash equivalents were $18.1 million as of June 30, 2024.